Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Biotronik launches new stent system for SFA disease treatment

Biotronik launches new stent system for SFA disease treatment

13th July 2010

Biotronik has introduced a new variety of medical stent which is designed to deliver unique benefits in the treatment of long disease segments in superficial femoral arteries (SFA) and infrapopliteal arteries.

The company’s new Pulsar-18 stent has been described as the world’s first 200 mm self-expanding stent designed for this application, with the product also optimised for compatibility with the firm’s 4F Solutions portfolio.

It offers advantages in areas such as radial force, flexibility and fracture resistance, and is designed to improve on the “moderate” results that stiffer stents generally provide in SFA disease treatment.

The product is launching this month in Europe and will be rolled out in other territories in the short-term future.

Alain Aimonetti, vice-president for sales and marketing at Biotronik said: “Pulsar-18 is the single most important addition to our already developed portfolio for lower limb intervention.”

Last month, Biotronik’s web-based patient monitoring technology Home Monitoring was recognised for its quality after winning the inaugural Cardiostim Innovation Award.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.